NovaBay Pharmaceuticals

ACTIVE

3800 N Central Ave Ste 460, 加利福尼亚州阿拉梅达县, California, United Stateswww.novabay.comPublic8 employeesEstablished: 2000-01-01

Also known as:

NBY

novabay pharmaceuticals, inc.

novabay

nby.us

nby.ca

niobay metals inc

Niobay Metals Inc is engaged in the acquisition, exploration, and evaluation of mineral properties. Its project includes the James Bay Niobium Project located in northern Ontario, Canada. Its other projects include the Crevier niobium, the tantalum project, and Foothills.

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2000

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

87.5%

Not Applicable

12.5%

Trial Status Distribution

Completed

75.0%

Unknown

25.0%

Clinical Trials

Trials sponsored by this organization (8)

Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora

Not Applicable

Unknown

interventional

May 2015100 participants

Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency

Phase 2

Unknown

interventional

Sep 2014140 participants

Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

Phase 2

Completed

interventional

Jun 2013217 participants

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

Phase 2

Completed

interventional

Aug 2012328 participants

Approvals

No approval data available

News

FDA Clears NovaBay's Novel Dual-Action Eye Infection Treatment NVC-422 for Clinical Trials

- NovaBay Pharmaceuticals receives FDA clearance for Investigational New Drug application of NVC-422, triggering a $1 million milestone payment from licensing partner Alcon. - NVC-422, the lead Aganocide compound, shows promise as the first treatment targeting both viral and bacterial conjunctivitis, addressing a significant gap in current therapeutic options. - The development targets the $1+ billion global ophthalmic anti-infective market, offering potential solution to increasing antibiotic resistance in bacterial conjunctivitis treatment.

Mar 2, 2025

Back to Organizations

NovaBay Pharmaceuticals

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (8)

Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora

Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency

Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis

Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation

Safety and Efficacy of Topical NVC-422 Gel in Impetigo

Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients

Approvals

News

FDA Clears NovaBay's Novel Dual-Action Eye Infection Treatment NVC-422 for Clinical Trials